Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

Celecoxib

For research use only.

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

62 publications

Celecoxib Chemical Structure

CAS No. 169590-42-5

Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 97 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Celecoxib has been cited by 62 publications

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MnP0SpVv[3Srb36gRZN{[Xl? Mn;tNE4yNTNyIN88US=> NYWyZlZUPDhiaB?= M3fTcIlv\HWlZYOgTWNCVS1zIHX4dJJme3Orb36gc44h[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVt NUTxcYV6OjZ3MUOxO|I>
H460 M1ztWmZ2dmO2aX;uJGF{e2G7 MnfPNE4yNTNyIN88US=> Ml\aOFghcA>? MljRbY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw> NWPVN5c6OjZ3MUOxO|I>
HKESC-2 M{Ozemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Hhe|IxyqEQvF2= M4rrblQ5yqCqwrC= M1rNSJNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>? NYK2[ng5OjZ2N{S2PVM>
CaES-17 MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DIPVIxyqEQvF2= NGLxfos1QMLiaNMg M333XZNq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>? M1rQdVI3PDd2Nkmz
HKESC-2 MXfBdI9xfG:|aYOgRZN{[Xl? NVHNUXhiOjEEoN88US=> M2fNW|Q5yqCqwrC= NELUPFZz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ NEC0PYgzPjR5NE[5Ny=>
CaES-17 NFPWW5pCeG:ydH;zbZMhSXO|YYm= M4XyNVIxyqEQvF2= NV7ETWJEPDkEoHlCpC=> M4WxfJJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> MXmyOlQ4PDZ7Mx?=
A549 MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTFSYo2NTF4MDFOwG0> M3jwdlQ5yqCqwrC= MnXTSG1UVw>? MoD6TWM2OD1zNkOuOEDPxE1? MofUNlY1PjR4NEO=
HCC827 M3PQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HwclUuOTZyIN88US=> M2XMWFQ5yqCqwrC= MWHEUXNQ MUXJR|UxRTZ7LkKg{txO MWSyOlQ3PDZ2Mx?=
A549 M165VGFxd3C2b4Ppd{BCe3OjeR?= NUK3fFc3QDBiwsXN Mom2OFjDqGkEoB?= MnfDSG1UVw>? MWPpcoR2[2W|IHHwc5B1d3Orcx?= MmfzNlY1PjR4NEO=
HCC827 M4P1fWFxd3C2b4Ppd{BCe3OjeR?= MkL2PFAhyrWP M1XRWlQ5yqCqwrC= NGPmTZhFVVOR MnvHbY5lfWOnczDhdI9xfG:|aYO= NETlPZQzPjR4NE[0Ny=>
SGC-7901/DDP MUjGeY5kfGmxbjDBd5NigQ>? NGPaXWgyOMLiwsXN NFn0OG8zPCCq M{TKVolvcGmkaYTzJIN6[2yxb4j5[4Vv[XOnLUKgZY5lKFBvZ3z5Z49xem:2ZXnuJIV5eHKnc4Ppc44> M1XnRVI3PDB5NkWz
SGC-7901  NUXCTnk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXCd3pWOjUEoHlCpC=> NXj0d45SUUN3ME2xNVUvODhizszN NXf3UoFwOjZ2MEe2OVM>
SGC-7901/DDP NV6yVXd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS4fo1COjUEoHlCpC=> NEL5c3ZKSzVyPUO1MlQ2KM7:TR?= NIrUVG4zPjRyN{[1Ny=>
SGC-7901/DDP NVLySI9sSXCxcITvd4l{KEG|c3H5 MYWxNOKhyrWP NVXXdIx6OjRiaB?= MUPpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKHerdHigZ4l{eGyjdHnu M1XUWFI3PDB5NkWz
SGC-7901/DDP M3\xcGZ2dmO2aX;uJGF{e2G7 NH\2Wm4yOMLiwsXN NFLHNXozPCCq NIDVfHNqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBRNWeueXPvdJJwfGWrbjD0bJJwfWeqIHLsc4NscW6pIFXQNkwh[W6mIHnuZYN1cX[jdHnu[{BRU0FiYX7kJGNTTUMEoB?= NXv4fpVDOjZ2MEe2OVM>
SGC-7901/DDP M3W3W2Z2dmO2aX;uJGF{e2G7 NIC3[JcyOMLiwsXN Mm\TNlQhcA>? M1vxV4NifXOnczDhJI1iemunZDDk[YNz\WG|ZTDpckB1cGVibHX2[Ywhd2ZiQnPsMVIheHKxdHXpci=> M{DhdFI3PDB5NkWz
H357 MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXsO{42NzFyIN88US=> NG[yTIY1QCCq M2naOWROW09? Mm\UbY5pcWKrdIOgZ4VtdCCpcn;3eIjDqGOxbXLpcoVlKHerdHigV4FjfXSxY3zhfC=> MmjPNlYxODl6N{S=
TAF MlvTSpVv[3Srb36gRZN{[Xl? MnLBNVDDqML3TR?= NIDqd2M4KGR? MWTh[oZm[3S|IGTBSpMh[WSqZYPpeoUheHKxcHXyeIlmew>? MomwNlU6QDdzMke=
TAF Ml3OSpVv[3Srb36gRZN{[Xl? NWDteJlwOTEEoNM1US=> MUGzNE0yOjBibXnu M1LjXJBwd3KueTDh[oZm[3S|IHTBb5QheGixc4Doc5J6dGG2aX;uJINwdnOncYXlcpQhfG9iRVfGJJNq\26jbHnu[y=> MYWyOVk5PzF{Nx?=
TAF MmnGSpVv[3Srb36gRZN{[Xl? M4\PSVExyqEEtV2= M2fLeFQ5KGh? MmHDbY5kemWjc3XzJGVITlJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MWmyOVk5PzF{Nx?=
PANC-1 NHnoWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rF[|IxNzZyL{GwNEDPxE1? MnHaNlQwPDhxN{KgbC=> NHLVfI1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NVHpfIhkOjV7N{OwOlI>
PANC-1 M3fHdGZ2dmO2aX;uJGF{e2G7 MYSyNE83OC9zMECg{txO MmTZNlQhcA>? MVTheJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA> MXSyOVk4OzB4Mh?=
HeLa  NF\S[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH3WIxvOjEEoN88UeKh MoTjNlTDqGh? NIixOFFmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?= NEjrWYwzPTd5MESyNy=>
SACC-83 MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvGNlDDqM7:TdMg NEXFT4wzPMLiaB?= MYXlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? NH;aPXozPTd5MESyNy=>
HeLa  MUjBdI9xfG:|aYOgRZN{[Xl? MVuyNOKh|ryPwrC= NWHRTo4xOjUEoHi= MUjlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygZZBweHSxc3nz M{DVU|I2PzdyNEKz
SACC-83 NIHQTZpCeG:ydH;zbZMhSXO|YYm= MlXTNlDDqM7:TdMg M2\KT|I1yqCq NIP0PJZmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{ MnnaNlU4PzB2MkO=
HeLa  MnznSpVv[3Srb36gRZN{[Xl? NVvtZ3gzOjBxNECvPFAh|ryP M2HpclI1yqCq NVjTVmg{fXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R? M2fhUFI2PzdyNEKz
SACC-83 MWHGeY5kfGmxbjDBd5NigQ>? MlHwNlAwPDBxOECg{txO MVSyOOKhcA>? NXnTeoMyfXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R? MViyOVc4ODR{Mx?=
HLCZ01 MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3yVmYx6oDVNkFCpOK2VQ>? NXjI[4FFPDhiaB?= Ml3hSG1UVw>? M3T4VIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NV:5TIs5OjV5MkS4PVk>
HLCZ01 NU\WZmxHTnWwY4Tpc44hSXO|YYm= MVW0NOKh|ryP NWjqXJQ5OjRiaB?= M1LwbGROW09? NIf0NlBqdmO{ZXHz[ZMh[WOldX31cIF1cW:wIH;mJGcxN0dzLYDoZZNmKGOnbHzzJINwdWKrbnXkJJdqfGhiSV\OMe6y MlXGNlU4OjR6OUm=
HLCZ01 M4TDc2Fxd3C2b4Ppd{BCe3OjeR?= NHTmXGQ1OMLizszN MVeyOEBp NGXaTlVFVVOR MYDlcohidmOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCLRl6t{tE> NWK5V|hNOjV5MkS4PVk>
HLCZ01 NXTUc5V4TnWwY4Tpc44hSXO|YYm= MVi0NOKh|ryP NYPzPGJzOjRiaB?= M2TyTmROW09? Mmr5bY5kemWjc3XzJHRTSUmOIHX4dJJme3Orb36gZ49u[mmwZXSge4l1cCCLboTldoZmem:wLd8x MofPNlU4OjR6OUm=
MGC803 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TyXlAuPjBizszN NYX1cGxIPzJiaB?= NInxTZNKSzVyPUS3MlI26oDLwsJihKk3NjR|IN88US=> MnPoNlU4ODF|N{i=
SGC7901 M4H6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH6NpgxNTZyIN88US=> MlvxO|IhcA>? MVjJR|UxRTR|LkWz5qCKyrIkgJm1MlEzKM7:TR?= M4LldVI2PzBzM{e4
MGC803 M1HiOmZ2dmO2aX;uJGF{e2G7 MoraOFDDqM7:TR?= NF\DUIY5NzF4L{K0JIg> MnvHeZBz\We3bHH0d{BE[mxvYjDlfJBz\XO|aX;u NXP3enl7OjV5MEGzO|g>
SGC7901 MVTGeY5kfGmxbjDBd5NigQ>? NEjnN5M1OMLizszN NEXyfYM5NzF4L{K0JIg> NVTxWW9rfXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v NWDEPFNMOjV5MEGzO|g>
MCF-7  NHvjcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\hNU8yOCEQvF2= NFjFOFc4OiCq MnT2SG1UVw>? NF3zSVNmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?= MWiyOVY3PzVzMB?=
MDA-MB-231  M4TBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;uPFEwOTBizszN MnrZO|IhcA>? NFXYVXJFVVOR NXfVXI1k\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= NX;wTXg4OjV4Nke1NVA>
MDA-MB-231 M17jOmZ2dmO2aX;uJGF{e2G7 MWGwMVQxKML3TR?= NXnqdms6PC1{NDDo NUn2WIJzcW6lcnXhd4V{KEORWD2yJJBzd3SnaX6g[ZhxemW|c3nvckBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MoDjNlU2QDd|Mkm=
MCF-7 MWDGeY5kfGmxbjDBd5NigQ>? MojqNE01OCEEtV2= NVLzOWw4PC1{NDDo NEfsRnBmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS|Ih\XiycnXzd4lwdsLi MnyzNlU2QDd|Mkm=
MCF7-MX  M2fERWZ2dmO2aX;uJGF{e2G7 M2LGRlAuPDBiwsXN MX60MVI1KGh? M{TCSoVvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? NUjCOFVFOjV3OEezNlk>
MDA-MB-231 NECyd4xHfW6ldHnvckBCe3OjeR?= M1\4eVAuPDBiwsXN Mke0OE0zPCCq NICw[IV{fGmvdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEGEQ1eyJJVxKHSxIESuNlchfGmvZYOgeI8h[2:wdILvcEBt\X[nbDDifUAyOiCqwrC= NHXrR4szPTV6N{OyPS=>
A2780 NW[yUWpnTnWwY4Tpc44hSXO|YYm= NXr3ZVlRPS9zMD:xOUDPxE1? MWe0PEBp MmrU[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFvQOJEzPTR{NEi5PC=>
SKOV3  NHnaT4xHfW6ldHnvckBCe3OjeR?= NIWzSYc2NzFyL{G1JO69VQ>? NXjRV5hEPDhiaB?= NXXQRWVT\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1HRV|I2PDJ2OEm4
A2780 NWfHOZhJTnWwY4Tpc44hSXO|YYm= M1vlPFUwOTBxMUWg{txO M2XycVQ5KGh? M4\2SYVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5? MV2yOVQzPDh7OB?=
SKOV3  MmLBSpVv[3Srb36gRZN{[Xl? NVLDbVJFPS9zMD:xOUDPxE1? M4ra[FQ5KGh? M1HVcIVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5? MnPqNlU1OjR6OUi=
A2780 Mnf0SpVv[3Srb36gRZN{[Xl? MoHvOU8yOC9zNTFOwG0> Mn3QOFghcA>? NILxb5ll\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6= M{DXcFI2PDJ2OEm4
SKOV3  NIrKSJJHfW6ldHnvckBCe3OjeR?= M{\hN|UwOTBxMUWg{txO M4r2XlQ5KGh? MXzk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5? NHPMV3ozPTR{NEi5PC=>
A2780 NWXtXpRZTnWwY4Tpc44hSXO|YYm= MV21M|ExNzF3IN88US=> M3nuSFEhcA>? MmHtbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUfwfnJQOjV2MkS4PVg>
SKOV3  NUDN[2pwTnWwY4Tpc44hSXO|YYm= MUe1M|ExNzF3IN88US=> Ml7jNUBp M1Xlbolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3PKOFI2PDJ2OEm4
HCT-15 NXLod3ZrTnWwY4Tpc44hSXO|YYm= NILaXncyOC13MDFOwG0> MXO2MVM3KGh? MUHpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ MXmyOVIyQDB{OB?=
HT-29  NGO2fFlHfW6ldHnvckBCe3OjeR?= NF:4UlkyOC13MDFOwG0> MX[2MVM3KGh? NWH5c2ZmcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MUeyOVIyQDB{OB?=
HSC3  M1W1eWNmdGxiVnnhZoltcXS7IFHzd4F6 MXGw5qCUPDBizszN MWG0PEBp NVXafYhEUUN3ME2yOU42yrFzLke4NEDPxE1? M{nSbVI2OTl6N{i5
HSC3  MXLBdI9xfG:|aYOgRZN{[Xl? NE[4NHgzPSEQvF2= MXO0PEBp MXTpcoR2[2W|IHHwc5B1d3Orcx?= Mon3NlUyQTh5OEm=
HSC3  NUfjVphpTnWwY4Tpc44hSXO|YYm= NX3YR3lWOjVizszN MXG0PEBp NWPTbotR\XiqaXLpeJMhe2mpbnnmbYNidnSueTDy[YR2[2WmIH3p[5JifGmxbjDjc41jcW6nZDD3bZRpKEOHVB?= NXzINYxMOjVzOUi3PFk>
HSC3  Ml;SSpVv[3Srb36gRZN{[Xl? M2TG[FI2KM7:TR?= M4nkWlQ5KGh? NHTTcXVqdmirYnn0d{BJW0N|IHPlcIwhcW64YYPpc44h[2:vYnnu[YQhf2m2aDDDSXQ> MUSyOVE6QDd6OR?=
HSC3  NUTINZZ6TnWwY4Tpc44hSXO|YYm= M3W5WVI2KM7:TR?= M4nrS|czKGh? NUjseZhK\GWlcnXhd4V{KE2PUD2yJIFv\CCPTWCtPUBxem:2ZXnud:Kh MmryNlUyQTh5OEm=
201T  MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fi[VczKGh? M173bGROW09? M3f5ZWlEPTB;NEiuOkDDvU1? MVGyOVA2Pzl2MR?=
273T NUn4NoN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVO4VFhKPzJiaB?= NGj1UGZFVVOR NF7FflNKSzVyPUiwMlUhyrWP Mn3ENlUxPTd7NEG=
Hep-2 M2PufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvzN|AwPTBxMUCwJO69VQ>? MmDSNVIwOjRxM{[vOFghcA>? Mn;wSG1UVw>? NGLm[ZBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NXvrZ3ZmOjR7OUi1OlQ>
Hep-2 M13rVWFxd3C2b4Ppd{BCe3OjeR?= NITsTGo2OCEQvF2= M{jEPFAuPDhiaB?= M{O5NGROW09? MmPHbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK= M3G4blI1QTl6NU[0
Hep-2 Mmn2SpVv[3Srb36gRZN{[Xl? NUfiTZEzPTBizszN M3ywflAuPDhiaB?= NVKwXWRNTE2VTx?= NF3ze45z\WS3Y3XzJJRp\SC2ZXzvcYVz[XOnIHHjeIl3cXS7IHfyZYR2[WyueR?= NF30b|EzPDl7OEW2OC=>
Hep-2 MXHGeY5kfGmxbjDBd5NigQ>? NH7lVFg2OCEQvF2= Mne1NE01QCCq M1yzVmROW09? NFruZpRl\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDoWGVTXA>? NInERYUzPDl7OEW2OC=>
SGC-7901 M2CyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXW4THVjOTBxNUCvNVAxKM7:TR?= NULtWVFOOjRxNEivO|IhcA>? NHTtdolFVVOR MlL5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MkXPNlQ6QTJ7NUi=
MKN-45 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUexNE82OC9zMECg{txO Ml[1NlQwPDhxN{KgbC=> MYTEUXNQ NHv5d2RqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NHzVSXEzPDl7Mkm1PC=>
SGC-7901 MkXDSpVv[3Srb36gRZN{[Xl? MUKxNE82OC9zMECg{txO M1vKTVQ5KGh? NWHKO2pqTE2VTx?= MULkc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NFHJeHczPDl7Mkm1PC=>
MKN-45 M33EN2Z2dmO2aX;uJGF{e2G7 NXjCepJYOTBxNUCvNVAxKM7:TR?= M3jqOFQ5KGh? NYrCTJpjTE2VTx?= MWfkc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NG\TboszPDl7Mkm1PC=>
C666-1 MYHDfZRwfG:6aXPpeJkhSXO|YYm= MYqyNE05OCEQvF2= M{nlT|I1KGh? NHzjc2pl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh MXKyOFg2PDh|OB?=
CNE-1 MonUR5l1d3SxeHnjbZR6KEG|c3H5 MVeyNE05OCEQvF2= MV[yOEBp NX7IRmZu\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? M3:3PFI1QDV2OEO4
CNE-2 NV\xcZRIS3m2b4TvfIlkcXS7IFHzd4F6 NXvXZ2pPOjBvOECg{txO NHj3ZlIzPCCq M4DT[IRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> NUDNe45[OjR6NUS4N|g>
C666-1 NFjrd3NEgXSxdH;4bYNqfHliQYPzZZk> NGLXNmw3OCEQvF2= NFfVR4M4KGR? MUTlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?= NVjpWY1uOjR6NUS4N|g>
CNE-1 MUPDfZRwfG:6aXPpeJkhSXO|YYm= NXe0[FE{PjBizszN M2fYN|ch\A>? MXLlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?= MWGyOFg2PDh|OB?=
SNU-1041 M3q1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXOwMVQxKM7:TR?= NUXhNoJ{PDhiaB?= NITIdGpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M3;jW|I1Pjl{N{Cz
SNU-1041 NX7rcXVHTnWwY4Tpc44hSXO|YYm= NF\UV4kzOC9|MDFOwG0> NFr0RZQ1KGh? NFzDOWRqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>? M3jwN|I1Pjl{N{Cz
SNU-1041 M3\FcWZ2dmO2aX;uJGF{e2G7 NX\2dmxJOC12MDFOwG0> NFi1VW41KGh? NFnnT2J2eC2{ZXf1cIF1\XNiQ1jPVOKh[W[2ZYKgeJJm[XSvZX70JJdqfGhiaHnnbEBkd26lZX70doF1cW:wcx?= Ml\oNlQ3QTJ5MEO=
SGC-7901 NXq3UIRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2K4RVUxNTF{NTFOwG0> M2fUe|I1NzR6L{eyJIg> NFW1e5dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M4PLXFI1Pjd4M{m0
SGC-7901 MWXBdI9xfG:|aYOgRZN{[Xl? MXGxNFAh|ryP Mnm4O|IhcA>? MnjLbY5lfWOnczDhdI9xfG:|aYO= MYGyOFY4PjN7NB?=
SGC-7901 MkHlSpVv[3Srb36gRZN{[Xl? NGPVW204PS9zMECvNVI2KM7:TR?= NWT1NohiOjRxNEivO|IhcA>? NXqxcoxlcW6lcnXhd4V{KGOjc4Dhd4UuQCCjbnSgMVkhdVKQQTDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCvYX7u[ZI> MnviNlQ3PzZ|OUS=
LMeC  M4jsV2Z2dmO2aX;uJGF{e2G7 MXGyNE82OCEQvF2= MYO0PEBp M2\meIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDwdo91\Wmw MUGyOFY2Pjd2Nh?=
CMeC-1 M4[1eWNmdGxiVnnhZoltcXS7IFHzd4F6 NV;DdIZyOjBxNUCg{txO MmTXOFghcA>? MoD0bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWLRdFZnOjR4NU[3OFY>
LMeC NX;4ZVh3S2WubDDWbYFjcWyrdImgRZN{[Xl? NYLyTGZMOjBxNUCg{txO MVq0PEBp M2j0d4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ Mn7BNlQ3PTZ5NE[=
CMeC-1 Mn;ESpVv[3Srb36gRZN{[Xl? MnXUNlAwPTBizszN MVK0PEBp M4nzTIlv\HWlZYOgS|EuWyCjcoLld5Q> M33jcVI1PjV4N{S2
LMeC NGHkOFlHfW6ldHnvckBCe3OjeR?= NVHOT|VSOjBxNUCg{txO NIXQSJg1QCCq NWHMXHBPcW6mdXPld{BIOS2VIHHydoV{fA>? NYnWXWxZOjR4NU[3OFY>
CMeC-1 MV;GeY5kfGmxbjDBd5NigQ>? NY\3UXF1OjBxNUCg{txO M3jKSlQ5KGh? MVrk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCleXPsbY4hTDFiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGi5OWQzPDZ3Nke0Oi=>
LMeC MXfGeY5kfGmxbjDBd5NigQ>? M{L4V|IxNzVyIN88US=> MWi0PEBp M4rJWYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MX:yOFY2Pjd2Nh?=
CMeC-1 M1\Oc2Z2dmO2aX;uJGF{e2G7 MlGzNlAwPTBizszN NHTq[5I1QCCq NIHtOG9qdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v MX[yOFY2Pjd2Nh?=
LMeC M3rP[2Z2dmO2aX;uJGF{e2G7 MoTTNlAwPTBizszN M{DWUVQ5KGh? MWPpcoR2[2W|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u NEDtU44zPDZ3Nke0Oi=>
OVCAR-3 NHjGVoxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NUTOdJNiOTBiwsXN MVmxJIg> MVflcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgc5ZiemmjbjDjZY5k\XJiY3XscEBl\WG2aNMg MmfQNlQ2OjB{Mke=
OVCAR-3 NGe0VWpCeG:ydH;zbZMhSXO|YYm= NEXpOmIyOCEEtV2= NX\HZ|MxOSCq Mn;RdJJwdW:2ZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIFxd3C2b4Ppd:Kh MXKyOFUzODJ{Nx?=
OVCAR-3 NHT5ZpdHfW6ldHnvckBCe3OjeR?= M4\TSlExKML3TR?= NVnIUol[OSCq Mnvn[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\S17wrC= Mn\INlQ2OjB{Mke=
OVCAR-3 MYfGeY5kfGmxbjDBd5NigQ>? NX\TfHhGOTBiwsXN NGDaO3IyKGh? Mlvq[I94di2{ZXf1cIF1\XNiTl[t{tpDKGGldHn2ZZRqd25iaX7keYNm\CCkeTDwZYNtcXSjeHXs NEfvdXUzPDV{MEKyOy=>
OVCAR-3 MWfGeY5kfGmxbjDBd5NigQ>? M1XLNlExKML3TR?= MXGxJIg> M2Da[4lvcGmkaYTzJJBi[2yrdHH4[YwucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v NHmyVoIzPDV{MEKyOy=>
CF33 NHTSUYJHfW6ldHnvckBCe3OjeR?= MkPkNVAxKM7:TR?= Mn7GNlQhcA>? MlTzbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDDU3guOiCycn;0[YlvKGW6cILld5Nqd25? NVX5R45QOjR3MEO3PFI>
CF33 NIL0SHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7N[|QyOC1zMECg{txO MlT4NE01KGR? M3nj[4lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M2i2SVI1PTB|N{iy
CF33 NETwb|NHfW6ldHnvckBCe3OjeR?= MkjINVAuOTByIN88US=> NWX0enNqPC1{NDDo M4DuN4Rm[3KnYYPld{Bk\WyuczDpckB1cGViUzDwbIF{\SCjbnSgbY5kemWjc3XzJINmdGy|IHnuJGcxN0dzIHHydoV{fA>? MXSyOFUxOzd6Mh?=
LNCaP MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX2dlEzNzVxMUCg{txO M{TaNFk3KGh? MUHpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XSxco\hd5RifGmw NGixPYwzPDJ7Nkm3PC=>
LNCaP NGXaT4RCeG:ydH;zbZMhSXO|YYm= NY\KT3FQOi93L{GwJO69VQ>? NWDRO2hNQTZiaB?= MU\pcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?= M3jGSVI1Ojl4OUe4
PC-3  M3LBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fyflAuPTBizszN NXT2XldJPDkkgJno MULpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MW[yOFEzPzh6Mh?=
PC-3  NEnlUldE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFjJNGExNTFyMDFOwG0> NWjNeXNSPzJiaB?= NXPs[Itw\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy Ml;INlQyOjd6OEK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Fibronectin / Vimentin / N-cadherin / E-cadherin ; 

PubMed: 28978083     


(A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells.

COX-2; 

PubMed: 29515134     


L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. 

pAKT / AKT / PPARγ / PTEN ; 

PubMed: 24721996     


Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h. 

28978083 29515134 24721996
Immunofluorescence
PPARγ / PTEN ; 

PubMed: 24721996     


Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.

24721996
Growth inhibition assay
Cell viability; 

PubMed: 28521485     


Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth. 

28521485
In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
- Collapse

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
- Collapse
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635
Smiles CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04526197 Enrolling by invitation Drug: ALXN1840|Drug: Celecoxib Wilson Disease Alexion Pharmaceuticals July 8 2020 Phase 1
NCT04447261 Recruiting Drug: BI 1356225|Drug: Placebo Obesity Boehringer Ingelheim June 30 2020 Phase 1
NCT03896113 Recruiting Drug: Celecoxib 200mg capsule Endometrium Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain November 13 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID